查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827419

2025-2032 年全球抗肥胖药物市场预测（依产品类型、剂型、给药途径及最终用户划分）

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，减重药物市场规模将成长至 70.7 亿美元，复合年增长率为 7.06%。

主要市场统计数据
基准年2024年 40.9亿美元
预计2025年 43.8亿美元
预测年份：2032年 70.7亿美元
复合年增长率（%） 7.06%

当代抗肥胖治疗环境的策略方向，重点关注临床进展、相关人员的期望以及持续计画成功的营运要求

减重药物治疗领域已从一个小众临床主题发展成为生物製药公司、支付者和医疗保健系统的主流策略重点。新型肠促胰岛素药物和联合治疗正在重塑人们对持续减重和代谢改善的临床期望，并重新激发了商业、临床和监管相关人员的兴趣。这种转变要求经营团队将快速的治疗创新与长期安全性、依从性策略和成本效益等实际因素相协调。

临床医生越来越多地将肥胖视为一种慢性疾病，需要持续的药物介入和生活方式的改变。为此，保险公司推出了强调疗效和基于价值的合约的有条件承保框架。同时，製造和分销生态系统正在适应注射剂和复杂生物製药的独特需求。这些交叉力量共同为寻求推出和扩大抗减肥药的组织创造了机会，也带来了复杂性。

本引言将重点放在创新、可及性和系统级准备的交汇，构成执行摘要的其余部分。下文将概述不断变化的治疗格局、关税相关的供应链影响、细分驱动的商业性考虑、区域动态、竞争格局、可行建议、调查方法以及决策者的最终优先事项。每个要素旨在为策略规划提供讯息，识别营运风险，并优先考虑短期和中期的高影响力干预措施。

科学突破、不断发展的报销模式以及新的交付方式如何重新定义减肥药的竞争动态和护理途径

在临床突破和支付模式演变的推动下，减肥药物市场格局正在改变。肠促胰岛素生物学和双促效剂平台的突破显着提升了疗效基准，改变了处方模式，并提高了人们对减肥和持续代谢益处的期望。这种科学动能正在引发一系列连锁反应，包括适应症扩大、仿单标示外适应症考虑以及竞争加剧，从而重塑了药物的生命週期规划和上市策略。

同时，报销框架也在改变。如今，付款方策略越来越强调长期疗效、分级诊疗以及将报销与绩效指标挂钩的新型合约模式。健康系统正在重新调整护理路径，将药物治疗纳入多学科肥胖管理项目，从而影响门诊、医院和居家照护机构的用药模式。此外，注射剂型的激增也带来了新的物流和患者教育需求，製造商必须满足这些需求，以确保患者依从性和实际疗效。

这些转变将要求企业从以产品为中心的产品发布模式转向整合的生态系统，将临床证据产生、病患支援服务和动态定价方法连结起来。能够展现持续成果、营运可扩展分销模式、并与付款方和供应商有效合作以降低长期取得门槛的企业，将实现策略差异化。

分析 2025 年美国关税调整将如何影响整个减肥药生态系统，包括采购、製造重组、付款人覆盖范围和准入策略

2025年美国关税调整对整个抗肥胖疗法价值链产生了连锁反应，加剧了依赖进口零件的脆弱性，并改变了最终产品的成本计算。生技药品和复杂小分子的原料采购通常跨越多个边境。半成品的关税增加了到岸成本，促使企业重新评估其供应商布局。为此，采购团队加快了供应商多元化，并考虑签订远期合约以对冲投入价格波动。

製造商也重新评估了其全球製造布局，并探索了近岸外包方案，以降低关税导致的价格波动风险。此类策略调整对生产力计画、技术转移时间表和监管备案有重大影响，因为转移生产基地或更改供应商名单需要耗时检验，甚至可能接受卫生部门的检查。对于对低温运输完整性和前置作业时间敏感的高需求注射药物而言，此类延误可能会推迟上市，并使库存规划复杂化。

支付方和供应商透过收紧处方集配置和加强使用控制来应对不断上涨的产品成本。同时，一些医疗保健机构专注于节省成本的替代方案，例如非药物干预措施和传统口服药物。同时，拥有垂直整合供应链和国内生产能力的製造商享有相对优势，确保了供应的连续性和更弹性价格设定。简而言之，主导压力强化了供应链弹性、监管敏捷性和积极的相关人员参与的策略价值，以维持病患可及性和商业性发展势头。

将产品形态、剂型、给药途径和最终用户设定与临床和商业性机会联繫起来的详细细分见解

基于细分市场的分析揭示了在治疗方案、剂量、给药途径和最终用户载体方面存在的差异化机会和限制，这些机会和限制将影响产品组合和商业策略。按产品类型划分，GLP-1促效剂和双重促效剂因其高效性而推动临床医生的需求，而纳曲酮-安非他酮、奥利司他、芬特明-托吡酯和SGLT2抑制剂等成熟药物仍然适用于特定患者群体和合併症主导的处方。由于作用机制和安全性各异，治疗顺序、合併策略和禁忌症管理仍是临床讯息的核心。

剂型考量对患者接受度和供应链设计有显着影响。注射剂市场（包括预填充笔和管瓶）需要强大的低温运输物流和全面的病患教育计划，以优化依从性。胶囊和片剂在处方便利性和便利性方面具有优势，当成本或患者偏好限制注射的使用时，这一点至关重要。因此，生命週期管理必须兼顾临床差异化和实际给药限制，以最大限度地提高不同环境的药物吸收率。

给药途径进一步加深了商业和临床策略的层次。注射途径，包括自动注射器、预填充註射笔和管瓶，需要在护理师和药剂师培训、远端监控支援以及设备人体工学方面进行投资，以减少给药障碍。鼻腔和口服途径提供差异化的价值提案，例如快速起效和便利性，可以扩大对注射犹豫患者的覆盖范围。最后，最终用户细分为诊所、居家医疗和医院，会影响分销选择、通路经济效益以及病患支援服务的设计。虽然诊所和医院门诊计画通常是急性病例的早期采用者，但居家照护服务正成为慢性治疗顺从性和长期保留的关键。

临床应用、付款人要求和监管复杂性的区域差异导緻美洲、欧洲、中东和非洲地区以及亚太地区采用不同的准入策略

每个地区的动态呈现不同的临床、监管和商业模式，需要独特的市场进入和规模化策略。在美洲，强大的支付方影响力、大规模的临床应用以及患者对有效疗法的旺盛需求，共同创造了一个竞争激烈的环境，其中长期疗效和成本效益的证据至关重要。能够与基于价值的合约和患者支援基础设施合作的製造商，很可能在专科诊所和更广泛的门诊网路中获得关注。

欧洲、中东和非洲是一个多元化的地区，其特点是监管环境、报销实务和临床基础设施水准存在差异。国家医疗保健系统和当地支付方通常要求更严格的卫生技术评估和比较有效性数据，因此，针对特定区域的证据生成和早期的卫生技术评估 (HTA) 参与尤为重要。在公共覆盖范围有限的市场中，私人支付和基于诊所的模式可能有助于推动早期采用，而与当地经销商的伙伴关係可以优化可及性。

亚太地区的特点是快速的都市区渗透、多样化的监管时间表以及公立和私立支付机构结构的混合。高人口密度和代谢性心臟疾病日益增长的盛行率使该地区具有重要的战略意义，但製造商必须应对价格敏感性、不同的处方习惯以及日益激烈的本地竞争。所有地区都需要采取一致的监管协调方法、本地临床数据生成和患者支持生态系统，才能将临床前景转化为永续的可近性和疗效。

竞争动态和企业策略将透过证据生成、供应弹性和综合患者解决方案决定抗减肥药的长期领导地位

减肥药领域的竞争格局由成熟製药公司和创新生物技术公司共同塑造。市场领导企业正利用深厚的临床开发能力来扩展适应症并建立头对头证据基础，而新参与企业则专注于差异化机制、设备创新和整合的患者支持提案。对于寻求加速产品线成熟度并扩大商业性覆盖范围的公司来说，策略伙伴关係、共同开发契约和收购是常见的做法。

将可靠的结果数据与可扩展的患者服务相结合的公司，很可能在付款人谈判和供应商招募方面拥有竞争优势。拥有强大製造地和供应链冗余的公司，在需求波动期间，更能维持供应连续性。同时，投资于设备人体工学、数位依从性工具和多学科护理模式的公司，将更有能力应对现实世界中在有效性和患者留存方面的挑战。

智慧财产权策略和生命週期管理计画也将决定公司的长期定位，尤其是在生物相似药和小分子药物竞争对手进入市场的情况下。积极主动地管理监管排他性、器械专利和配方改进可以延长公司的商业性可行性。最终，那些将临床差异化与卓越营运和以付款人为主导的证据相结合的公司，将在将科学前景转化为持续的患者可及性方面占据领先地位。

为製造商和相关人员提供具有影响力且可行的建议，以确保获得药物、加强供应链并最大化现实世界的治疗价值

产业领导者应优先考虑一系列可行的干预措施，将临床前景转化为持续的商业性成果。首先，投资制定分阶段的证据产生计划，将关键临床试验数据与旨在证明持续代谢和生活品质益处的务实真实世界试验相结合。儘早与付款方和健康技术管理局 (HTA) 机构合作，协调终点和证据包，可以减少下游的可及性摩擦。

第二，透过多元化供应商、加快替代设施的资格认证以及在适当情况下考虑近岸外包来增强供应链的韧性，以降低海关和物流风险。对于注射药物，同时投资低温运输能力和库存管理系统至关重要。第三，设计患者支持模式，以解决初始用药和长期用药依从性问题。进行多通路注射技术教育，利用数位化用药依从性工具，并与诊所和居家照护机构合作，以确保护理的连续性。

第四，采用灵活的商业模式，例如基本契约、阶梯定价和针对特定适应症的处方策略。将通讯和病人历程与给药途径和剂型偏好相结合，并优化设备设计以减少摩擦。最后，在分销、远端医疗整合和本地证据生成方面开展策略合作，以加速异质区域市场的可及性。同时执行这些行动将显着提高持续采用和付款人协调的可能性。

严格的多方法研究框架，结合相关人员访谈、监管调查、临床证据综合和情境分析，得出策略结论

本执行摘要所依据的研究结合了多种方法，以确保获得均衡且可操作的见解。我们与内分泌和肥胖临床医生、医院药房主任、付款方政策主导者以及供应链高管进行了初步定性访谈，以确定近期营运风险和应用驱动因素。我们还系统地审查了监管和临床指南文件以及公共临床试验註册中心，以检验影响治疗定位、安全信号和覆盖范围讨论的终点事件。

定量综合分析从公共卫生数据、临床试验结果和产品核可中提取处方趋势，以绘製采用轨迹并识别以管道为中心的需求讯号。运用情境规划技术评估不同成本和供应条件下关税、生产迁移时间表以及潜在付款人反应的影响。最后，由商业、医学和监管专家参与的跨职能研讨会指导制定切实可行的建议，以平衡临床严谨性与商业性现实。

品质保证措施包括跨多个资料来源的三角测量、关键发现的专家检验以及供应链假设的敏感度分析。最终的调查方法优先考虑透明度、可复製性和策略相关性，以支援经营团队决策。

对研究结果的全面回顾强调了协作证据、供应弹性和本地化访问策略的必要性，以将临床创新转化为可持续的患者结果。

现代减肥药物市场环境的特征是前所未有的治疗潜力和复杂的可及性动态。科学创新提高了疗效标准，并改变了人们对慢性病管理的期望，但可及性和可负担性的考量，加上供应链和监管的复杂性，正在减缓这些治疗方法转化为人群层面影响的速度。因此，决策者必须整合临床、营运和商业规划，才能实现长期价值。

永续的成功将有利于那些积极主动地将证据产生与付款方期望相结合、建立具有韧性和灵活性的供应链、并设计以患者为中心的交付模式以减少依从性障碍的机构。区域差异性要求制定在地化策略，在尊重监管规范和付款方决策框架的同时，充分利用全球证据。总而言之，需要跨职能部门和相关人员的协作行动，将临床进展转化为有意义且公平的病患治疗结果。

这一结论强调了及时、基于证据的策略执行的必要性。那些果断采取行动，将临床创新与切实可行的可及性解决方案相结合的公司，将在快速发展的治疗领域中获得先发优势。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 医生处方中 GLP-1 受体促效剂联合治疗用于体重管理的趋势不断发展
  • 付款人实施分步编辑通讯协定以管理新型抗肥胖药物不断上涨的成本
  • 直接面向消费者的行销宣传活动推动了患者对注射减重治疗的需求
  • 口服 GLP-1促效剂的出现彻底改变了肥胖治疗中的患者依从性
  • GIP 和 GLP-1 双重促效剂的 III 期试验已证明具有显着的减重和代谢益处。
  • 针对减肥药取得和治疗结果方面的种族和社会经济差异的健康公平倡议
  • 整合肥胖指导和处方药依从性监测的远端医疗平台
  • 生技Start-Ups利用精准医疗开发以胜肽为基础的减重治疗方法

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：按产品类型分類的抗肥胖药物市场

  • GLP-1促效剂
  • 纳曲酮安非他酮
  • 奥利司他
  • 芬特明/托吡酯
  • Sglt2抑制剂

第九章 抗肥胖药物市场（按剂型）

  • 胶囊
  • 注射
    • 预填充笔
    • 管瓶
  • 药片

第 10 章。按给药途径分類的抗肥胖药物市场

  • 注射
    • 自动注射器
    • 预填充笔
    • 管瓶
  • 鼻腔
  • 口服

第 11 章。 抗肥胖药物市场（按最终用户）

  • 诊所
  • 居家照护环境
  • 医院

第 12 章：按地区分類的减重药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章：按类别分類的抗肥胖药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各国抗肥胖药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Amgen Inc.
    • Zealand Pharma A/S
    • Gelesis, Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market is projected to grow by USD 7.07 billion at a CAGR of 7.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.09 billion
Estimated Year [2025] USD 4.38 billion
Forecast Year [2032] USD 7.07 billion
CAGR (%) 7.06%

A strategic orientation to the modern anti-obesity therapy environment emphasizing clinical advances, stakeholder expectations, and operational imperatives for sustained program success

The therapeutic landscape for anti-obesity drugs has evolved from a niche clinical conversation into a mainstream strategic priority for biopharma, payers, and health systems. Novel incretin-based agents and combination therapies have reshaped clinical expectations for durable weight loss and metabolic benefit, prompting fresh interest across commercial, clinical, and regulatory stakeholders. This shift requires executives to reconcile rapid therapeutic innovation with real-world considerations such as long-term safety, adherence modalities, and cost-effectiveness.

Clinicians are increasingly viewing obesity as a chronic disease that demands sustained pharmacologic intervention alongside lifestyle modification. Payers are responding with conditional coverage frameworks that emphasize outcomes and value-based contracting. Simultaneously, manufacturing and distribution ecosystems are adapting to the unique requirements of injectable formulations and complex biologics. Taken together, these cross-cutting forces create both opportunity and complexity for organizations seeking to launch or scale anti-obesity therapeutics.

This introduction frames the rest of the executive summary by highlighting the intersection of innovation, access, and systems-level readiness. The following sections outline the transformative shifts in the therapeutic landscape, tariff-related supply chain implications, segmentation-driven commercial insights, regional dynamics, competitive positioning, actionable recommendations, methodological underpinnings, and concluding priorities for decision-makers. Each element is intended to inform strategic planning, identify operational risks, and prioritize high-impact interventions for near- and mid-term horizons.

How scientific breakthroughs, evolving reimbursement models, and new delivery modalities are jointly redefining competitive dynamics and care pathways in obesity therapeutics

The anti-obesity drug landscape is undergoing transformative shifts driven by simultaneous clinical breakthroughs and evolving payer paradigms. Breakthroughs in incretin biology and dual-agonist platforms have materially raised efficacy benchmarks, altering prescribing patterns and elevating expectations for sustained metabolic benefit beyond weight reduction alone. This scientific momentum has catalyzed a cascade of label expansions, off-label prescribing considerations, and intensified head-to-head competition, which in turn is reshaping life-cycle planning and commercial launch strategies.

Concurrently, reimbursement frameworks are adapting. Payer strategies now increasingly emphasize longitudinal outcomes, tiered access, and novel contracting models that tie reimbursement to performance metrics. Health systems are reorienting care pathways to integrate pharmacotherapy into multidisciplinary obesity management programs, which affects utilization patterns across ambulatory clinics, hospitals, and homecare settings. Additionally, the proliferation of injectable delivery formats has introduced new logistics and patient education imperatives that manufacturers must address to ensure adherence and real-world effectiveness.

Together, these shifts require companies to pivot from product-centric launches toward integrated ecosystem plays that align clinical evidence generation, patient support services, and dynamic pricing approaches. Strategic differentiation will be achieved by those who can demonstrate durable outcomes, operationalize scalable distribution models, and collaborate effectively with payers and providers to lower barriers to long-term access.

An analysis of how the 2025 U.S. tariff adjustments reverberated through procurement, manufacturing realignment, payer coverage, and access strategies across the obesity drug ecosystem

U.S. tariff adjustments in 2025 created a ripple effect across the anti-obesity therapeutic value chain, amplifying vulnerabilities in import-dependent components and altering cost calculus for finished products. Raw material sourcing for biologics and complex small molecules often crosses multiple borders; tariffs on intermediate goods increased landed costs and incentivized firms to reevaluate supplier footprints. In response, procurement teams accelerated supplier diversification and explored forward contracts to hedge input-price volatility.

Manufacturers also reassessed global manufacturing footprints and considered nearshoring options to reduce exposure to tariff-induced price swings. This strategic realignment carries nontrivial implications for capacity planning, technology transfer timelines, and regulatory submissions, since moving production or altering supplier lists requires time-consuming validation and potential inspections by health authorities. Those delays can defer launches and complicate inventory planning for high-demand injectables, which are sensitive to cold-chain integrity and lead times.

Payers and providers reacted to increased product costs by tightening formulary placement and intensifying utilization management. Coverage policies leaned more heavily on prior authorization criteria tied to comorbidity profiles and demonstrated response, while some health systems increased their emphasis on cost-mitigating alternatives such as nonpharmacologic interventions or legacy oral agents. At the same time, manufacturers with vertically integrated supply chains or domestic production capability enjoyed a relative advantage, securing continuity of supply and greater pricing flexibility. In sum, tariff-driven pressures reinforced the strategic value of supply chain resilience, regulatory agility, and proactive stakeholder engagement to preserve patient access and commercial momentum.

Detailed segmentation insights linking product modality, dosage form, administration route, and end-user settings to distinct clinical and commercial opportunities

Segmentation-based analysis reveals differentiated opportunities and constraints across therapeutic, dosage, administration, and end-user vectors that should shape portfolio and commercial strategies. Based on product type, GLP-1 agonists and dual-agonist modalities are driving clinician demand through high-efficacy outcomes, while established agents such as naltrexone-bupropion, orlistat, phentermine-topiramate, and SGLT2 inhibitors retain relevance for specific patient cohorts and comorbidity-driven prescribing. Differing mechanisms of action and safety profiles mean that treatment sequencing, combination strategies, and contraindication management will remain central to clinical messaging.

Dosage form considerations materially influence patient adoption and supply chain design. The market's injectable formats, which include prefilled pens and vials, demand robust cold-chain logistics and comprehensive patient education programs to optimize adherence. Capsules and tablets retain advantages in convenience and prescribing simplicity, which can be critical where cost or patient preference limits injectable uptake. Consequently, lifecycle management must account for both clinical differentiation and practical delivery constraints to maximize uptake across diverse settings.

Route of administration further stratifies commercial and clinical strategies. Injectable pathways, including autoinjectors, prefilled pens, and vials, require investment in nurse and pharmacist training, remote monitoring support, and device ergonomics to reduce administration barriers. Nasal and oral routes offer differentiated value propositions for rapid onset or convenience, which can expand reach among patients with injection hesitancy. Finally, end-user segmentation into clinics, homecare settings, and hospitals influences distribution choices, channel economics, and the design of patient support services. Clinics and hospital outpatient programs often serve as early adopters for higher-acuity cases, while homecare services are increasingly central to chronic therapy adherence and long-term retention.

Regional variations in clinical adoption, payer requirements, and regulatory complexity driving differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exhibit distinct clinical, regulatory, and commercial contours that require tailored strategies for market entry and scale-up. In the Americas, strong payer influence, large-scale clinical adoption, and high patient demand for efficacious therapies create a competitive environment where evidence of long-term outcomes and cost-effectiveness is paramount. Manufacturers that can align with value-based contracting and patient-support infrastructure will find traction in both specialty clinics and broader ambulatory networks.

Europe, Middle East & Africa presents a heterogeneous landscape characterized by variable regulatory pathways, divergent reimbursement philosophies, and differing levels of clinical infrastructure. National health systems and regional payers often require more rigorous health technology assessments and comparative-effectiveness data, which increases the importance of region-specific evidence generation and early HTA engagement. In markets where public coverage is constrained, private pay and clinic-based models may drive initial uptake, and partnerships with regional distributors can optimize access.

Asia-Pacific is defined by rapid adoption in urban centers, diverse regulatory timelines, and a mix of public and private payer structures. High population density and increasing prevalence of cardiometabolic comorbidities make the region strategically critical, but manufacturers must navigate price sensitivity, differential prescribing practices, and growing local competition. Across all regions, a coherent approach to regulatory harmonization, local clinical data generation, and tailored patient-support ecosystems will be necessary to translate clinical promise into sustainable access and outcomes.

Competitive dynamics and corporate strategies that determine long-term leadership in anti-obesity therapeutics through evidence generation, supply resilience, and integrated patient solutions

Competitive positioning in the anti-obesity therapeutics arena is being shaped by a mix of established pharmaceutical companies and innovative biotechnology entrants. Market leaders are leveraging deep clinical development capabilities to expand indications and generate head-to-head evidence, while newer entrants are focusing on differentiated mechanisms, device innovation, or integrated patient-support propositions. Strategic partnerships, co-development agreements, and acquisitions are common as firms seek to accelerate pipeline maturation and extend commercial reach.

Companies that integrate robust outcomes data with scalable patient services will gain a competitive edge in payer negotiations and provider adoption. Those with strong manufacturing footprints and supply chain redundancy demonstrate advantage in maintaining continuity of supply during demand fluctuations. In parallel, firms investing in device ergonomics, digital adherence tools, and multidisciplinary care models are better positioned to address real-world effectiveness and retention challenges.

Intellectual property strategies and lifecycle management plans will also determine long-term positioning, particularly as biosimilar and small-molecule competitors enter the mix. Proactive management of regulatory exclusivities, device patents, and formulation improvements can extend commercial viability. Ultimately, companies that align clinical differentiation with operational excellence and payer-centric evidence will lead in converting scientific promise into sustained patient access.

High-impact, implementable recommendations for manufacturers and stakeholders to secure access, strengthen supply chains, and maximize real-world therapeutic value

Industry leaders should prioritize a set of actionable interventions that connect clinical promise to durable commercial outcomes. First, invest in a phased evidence generation plan that pairs pivotal trial data with pragmatic real-world studies designed to demonstrate sustained metabolic and quality-of-life benefits. Early engagement with payers and HTA bodies to align endpoints and evidence packages can reduce downstream access friction.

Second, strengthen supply chain resilience by diversifying suppliers, accelerating qualification of alternate sites, and exploring nearshoring where appropriate to mitigate tariff and logistical risk. Parallel investments in cold-chain capacity and inventory management systems will be crucial for high-demand injectables. Third, design patient support models that address initiation and long-term adherence: build multichannel education for injection technique, leverage digital adherence tools, and coordinate with clinics and homecare providers to create continuity of care.

Fourth, adopt flexible commercial models that include outcomes-based contracting, tiered pricing, and indication-specific formulary strategies. Tailor messaging and patient journeys to administration route and dosage form preferences, and optimize device design to reduce friction. Finally, pursue strategic collaborations for distribution, telehealth integration, and local evidence generation to accelerate access across heterogeneous regional markets. Executing these actions in parallel will materially enhance the probability of sustained uptake and payer alignment.

A rigorous multi-method research framework combining stakeholder interviews, regulatory review, clinical evidence synthesis, and scenario analysis to drive strategic conclusions

The research underpinning this executive summary combined a multi-method approach to ensure balanced, actionable insights. Primary qualitative interviews were conducted with clinicians across endocrinology and bariatric medicine, hospital pharmacy directors, payer policy leads, and supply chain executives to surface near-term operational risks and adoption drivers. Regulatory and clinical guidance documents were systematically reviewed alongside public trial registries to validate therapeutic positioning, safety signals, and endpoints shaping coverage discussions.

Quantitative synthesis drew on prescription trends from public health data, clinical trial outcome reporting, and product approvals to map adoption trajectories and identify channel-centric demand signals. Scenario planning techniques were applied to evaluate tariff impacts, manufacturing reallocation timelines, and potential payer responses under varying cost and supply conditions. Finally, cross-functional workshops with commercial, medical affairs, and regulatory experts informed the development of pragmatic recommendations that balance clinical rigor with commercial reality.

Quality assurance measures included triangulation across multiple data sources, validation of key findings with subject-matter experts, and sensitivity analysis around supply chain assumptions. The resulting methodology prioritizes transparency, replicability, and strategic relevance to support executive decision-making.

Concluding synthesis underscoring the necessity of coordinated evidence, supply resilience, and localized access strategies to convert clinical innovation into sustained patient outcomes

The contemporary anti-obesity drug environment is defined by unprecedented therapeutic potential and complex access dynamics. Scientific innovation has raised the bar for efficacy and shifted expectations around chronic disease management, yet access and affordability considerations, coupled with supply chain and regulatory complexity, temper the pace at which those therapies translate to population-level impact. Decision-makers must therefore integrate clinical, operational, and commercial planning to realize long-term value.

Sustainable success will favor organizations that proactively align evidence generation with payer expectations, build resilient and flexible supply chains, and design patient-centric delivery models that reduce adherence barriers. Regional heterogeneity demands localized strategies that respect regulatory norms and payer decision-making frameworks while leveraging global evidence. Taken together, the path forward requires coordinated action across functions and stakeholders to convert clinical advances into meaningful, equitable patient outcomes.

This conclusion underscores the imperative for timely, evidence-informed strategy execution: firms that move decisively to reconcile clinical innovation with pragmatic access solutions will capture the first-mover advantages in a rapidly evolving therapeutic category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Physician prescribing preferences evolving toward GLP-1 receptor agonist combination therapies for weight management
  • 5.2. Payers implementing step edit protocols to manage rising costs of novel anti-obesity medications
  • 5.3. Direct to consumer marketing campaigns driving patient demand for injectable obesity treatments
  • 5.4. Emergence of oral GLP-1 agonist formulations transforming patient adherence in obesity care
  • 5.5. Phase III trials of dual GIP and GLP-1 agonists demonstrating superior weight loss and metabolic benefits
  • 5.6. Health equity initiatives targeting racial and socioeconomic disparities in obesity drug access and outcomes
  • 5.7. Telehealth platforms integrating obesity coaching with prescription medication adherence monitoring
  • 5.8. Biotech startups leveraging precision medicine to develop peptide based therapies for targeted weight reduction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Drugs Market, by Product Type

  • 8.1. Glp-1 Agonists
  • 8.2. Naltrexone Bupropion
  • 8.3. Orlistat
  • 8.4. Phentermine Topiramate
  • 8.5. Sglt2 Inhibitors

9. Anti-Obesity Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectables
    • 9.2.1. Prefilled Pens
    • 9.2.2. Vials
  • 9.3. Tablets

10. Anti-Obesity Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Autoinjector
    • 10.1.2. Prefilled Pen
    • 10.1.3. Vial
  • 10.2. Nasal
  • 10.3. Oral

11. Anti-Obesity Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Anti-Obesity Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Obesity Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Obesity Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Novo Nordisk A/S
    • 15.3.2. Eli Lilly and Company
    • 15.3.3. Pfizer Inc.
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Amgen Inc.
    • 15.3.7. Zealand Pharma A/S
    • 15.3.8. Gelesis, Inc.
    • 15.3.9. F. Hoffmann-La Roche AG
    • 15.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 325. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 328. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 329. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 339. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 342. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 343. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-20